{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Barriers to receiving home administration were assessed using binary (yes/no) questionnaire administered at Cycle 4. Participants were asked whether they experienced any barriers to home infusion, including delays in treatment related to delivery of medication, arrival time of the infusion nurse, issues related to storage of medication, issues related to administration of the medication. The outcome reflects the total number of participants who responded, \"yes\" to any barriers to home based therapy, based on binary (yes/no) questionnaire.","groups":[{"description":"Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.\n\nDaratumumab and Hyaluronidase-fihj: Given SC\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nInterview: Ancillary studies","id":"OG000","title":"Treatment (daratumumab and hyaluronidase-fihj)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received Darzalex-Faspro in the home setting during cycles 3-6.","reportingStatus":"POSTED","timeFrame":"At Visit 4, Day 85","title":"Number of Patients Reporting Barriers to Home Administration At Cycle 4","type":"SECONDARY","unitOfMeasure":"Participants"}